IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Immunomedics Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, Calif.--()--Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Immunomedics Inc. (“Immunomedics” or the “Company”) (Nasdaq: IMMU). Investors who purchased or otherwise acquired shares between April 20, 2016 and June 2, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August 8, 2016, lead plaintiff motion deadline.

If you purchased shares of Immunomedics during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, Immunomedics issued false and misleading statements to investors and/or failed to disclose: that the Company’s abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting contained previously disclosed results from a mid-stage study; that Immunomedics misrepresented to ASCO that the abstract contained only updated and previously undisclosed data; and that as a result of this ASCO removed the IMMU-132 presentation from the 2016 ASCO Annual Meeting schedule.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at

This press release may constitute Attorney Advertising in some jurisdictions.


Khang & Khang LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474

Khang & Khang LLP